Trial Profile

Evaluating the Effect of Two Dosing Regimens of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex Lid Infestation

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lotilaner (Primary)
Indications Meibomian gland dysfunction
Focus Adverse reactions
Acronyms Rhea
Sponsors Tarsus Pharmaceuticals

Most Recent Events

13 Nov 2024 According to a Tarsus Pharmaceuticals media release, the company presented new positive data from the study at the American Academy of Optometry Annual Meeting on November 7, 2024
06 Apr 2024 Status changed from recruiting to active, no longer recruiting.
22 Mar 2024 Planned End Date changed from 15 Jan 2024 to 15 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com